Posts

Beeline reports positive Phase 2 results for lupus drug afimetoran

on
Beeline Medicines presented detailed Phase 2 results for afimetoran, an oral lupus drug originally developed by Bristol Myers Squibb, at the American College of Rheumatology’s 2026 meeting. In a 248-person trial of systemic lupus erythematosus (SLE), all three daily doses met the primary endpoint at Week 48. SRI-4 response rates were 67.8%, 64.1% and 66.1%, versus 34.4% with placebo—an adjusted placebo difference of about 30–32 percentage points. Secondary measures generally favored afimetoran, including lupus disease activity, skin and joint symptoms, and corticosteroid reduction. For example, 71.9%–75% of participants on afimetoran reached or maintained a daily steroid dose of 7.5 mg or less, versus 50% on placebo. The company reported serious adverse events in 5.9% of afimetoran-treated participants versus 12.9% on placebo; treatment discontinuations due to side effects were 3.2% versus 9.7%. These are trial findings, not proof of comparative safety in broader use. Afimetora...

Neurosterix raises $105 million to advance schizophrenia drug

on

Blackstone to fund up to $1.5 billion of Pfizer’s berobenatide development

on

Analysis: Raising German drug prices could raise costs on both sides

on

VectorY raises $83.5 million to advance experimental neurodegenerative-disease therapies

on

FDA approves Merck’s Abbisko-licensed drug for rare joint tumor

on

Capricor and NextCure disclose layoffs amid FDA review and merger preparations

on

FDA requires rare eye-condition warning on GLP-1 drug labels

on

Flagship combines Valo and Montai

on

PepGen’s early Phase 2 data lift shares as Ionis and ImmunityBio fall

on

Beam reports positive Phase 1/2 results for base-edited sickle cell therapy

on

Democrats step up scrutiny of confidential MFN drug deals

on

aTyr Pharma files to sell up to $80 million in stock

on